November 12, 2021 07:00 AM EST
R&D

Cor­texyme low­ers dose amid safe­ty con­cerns, rais­ing ques­tions about fu­ture of off­beat Alzheimer’s ap­proach

Jason Mast

Editor

Late last month, Cor­texyme an­nounced a sub­set of pa­tients saw their cog­ni­tive de­cline slow while tak­ing the high dose of the com­pa­ny’s ex­per­i­men­tal Alzheimer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times